reason report
exparel growth track pt reflect increas
invest iovera
bottom line maintain view exparel growth trajectori
potenti entri heron op
hesit give much credit iovera better
visibl return pacira plan invest
lower price target reflect increas spend
iovera ou commerci organ reiter market
perform rate exparel show respect growth rate low
year market driven new indic nerv block
expand use ambulatori surgic set increas use
orthoped surgeri type compani increas invest
recent acquir asset iovera street includ us still
intrigu market potenti iovera await better visibl
commerci potenti
expans set orthoped fuel exparel
growth sinc american dental associ issu
uniqu reimburs code exparel ambulatori surgic
set take effect januari pacira made headway gain
payer reimburs access cover exparel nation
sever larg blue also includ exparel fee
schedul work mechan adjust
coverag exparel continu expand major nation
commerci payer remaind year driver
exparel growth orthoped particularli shoulder spine
fractur surgeri op partnership enhanc
exparel posit anesthesiologist field block
exparel clinic regulatori progress remain track
phase trial pk profil safeti exparel patient
year old enrol track complet end
year manag comment indic compani
current top prioriti hope file snda launch
compani also expect report top-lin result second
phase choic trial opioid reduct c-section later year
includ endpoint complet opioid spare on-going
studi includ phase studi hip spine fractur outsid
us exparel recent valid compani
expect chmp opinion manag comment
compani submit nda canada soon partner
nuanc biotech develop exparel china
dcf use wacc
termin growth rate
net debt total capit
per share net cash includ short-
term long-term invest
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
pacira view larg osteoarthr market opportun
iovera pacira focu two major opportun iovera
osteoarthr patient one patient undergo total knee
arthroplasti tka one fail
conserv therapi want undergo surgeri tka
set iovera could given surgeri prepar patient
follow exparel surgeri provid month pain
relief surgeri long-last effect iovera also fit well
need patient second bucket seek long-
term pain relief want delay surgeri manag believ
osteoarthr patient us offer target market potenti
expect iovera net sale grow within year
pacira process develop new price strategi iovera
drive growth compani invest clinic studi
demonstr valu proposit iovera initi focu tka
anterior cruciat ligament acl repair iovera combin
exparel pacira plan rais averag sell price asp
per smart tip within month carri addit volume-bas
discount manag comment current payment hospit
outpati hopd set allow hospit
make good margin propos asp inform
manag new code cover destruct three
genicular nerv becom effect januari rais
reimburs amount hopd set
agre new code could give surgeon
confid reimburs also note profit margin
use appear significantli differ
pacira need figur appropri price strategi
cost handheld devic critic adopt
new spend guidanc driven primarili spend iovera
manag continu believ gross margin track averag
eventu improv gross margin
outlier impact sever week shutdown
consist typic season increas sg guidanc
primarili driven inclus commerci infrastructur cost
iovera manag expect spend rate continu
especi pacira effect relaunch iovera next year
remain uncertain whether iovera revenu off-set
increment invest pt increas forecast iovera
sale slightli total revenu
forecast higher higher
revenu forecast consensu
consensu due entri also
rais estim sg estim
account increment invest pacira
plan iovera chang result oper margin
basi point lower previou estim ep
forecast lower consensu
consensu price
target lower result
believ pacira exparel non-opioid post-op pain manag
continu grow driven commerci collabor unbundl
sale believ long-term growth may impact
entri heron better clinic profil -- longer durat pain relief hour
vs hour easier administr instil vs infiltr base medacorp
survey believ posit tailwind unbundl set gradual
could increas time initi analysi suggest competit impact
temper impact rate pacira stock market perform mp price target
pt base dcf forecast cash flow use
wacc termin growth rate
phase iv studi success limit impact collabor potenti competit
heron iovera may gain much adopt due econom
note number
figur chang model
svb leerink estim note number except ep
note revenu
changevalu changevarianceconsensusactu vs constherapeut product licens mileston dilut non-gaap adjustmentstot one-tim net pacira bioscienc inc
svb leerink llc equiti research compani file
brand
type event
event trial detail
date known
up/down
view
top-lin result opioid-fre c-
top-lin result studi
cardiovasular spine surgeri
top-lin result hip fractur studi
number except per share data
net debt ebitda ratio
figur except per share data
collabor licens develop revenu
sourc press releas transcript sec file
number except per share data
prepaid expens
current portion defrer revenu
accumul comprehens loss
number except per share data
adjust reconcil ni net cash oper
amort unfavor leas oblig debt issuanc cost
amort debt discount
loss dispos fix asset
loss extinguish debt
decreas increas work capit
purchas fix asset capital-expenditure
purchas invest
sale invest
payment conting consider
net invest
proce exercis stock option warrant
proce share issu employe stock purchas plan
convers princip equiti compon convert senior
net financ
net chang equival
number except per share data
chang work capit
